NASDAQ:AVEO

AVEO Pharmaceuticals Stock Forecast, Price & News

$6.74
+0.13 (+1.97 %)
(As of 09/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$6.53
$6.79
50-Day Range
$5.12
$6.89
52-Week Range
$4.95
$18.24
Volume248,902 shs
Average Volume1.21 million shs
Market Capitalization$231.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
30 days | 90 days | 365 days | Advanced Chart
Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


AVEO Pharmaceuticals logo

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

323rd out of 1,352 stocks

Pharmaceutical Preparations Industry

148th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

Is AVEO Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVEO Pharmaceuticals stock.
View analyst ratings for AVEO Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than AVEO Pharmaceuticals?

Wall Street analysts have given AVEO Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AVEO Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for AVEO Pharmaceuticals
.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. The biopharmaceutical company earned $7.56 million during the quarter, compared to analyst estimates of $7.76 million. AVEO Pharmaceuticals had a negative net margin of 398.34% and a negative trailing twelve-month return on equity of 107.25%.
View AVEO Pharmaceuticals' earnings history
.

How has AVEO Pharmaceuticals' stock price been impacted by COVID-19?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVEO shares have increased by 93.1% and is now trading at $6.74.
View which stocks have been most impacted by COVID-19
.

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

Shares of AVEO Pharmaceuticals reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

3 analysts have issued twelve-month price targets for AVEO Pharmaceuticals' shares. Their forecasts range from $9.00 to $19.00. On average, they expect AVEO Pharmaceuticals' share price to reach $15.33 in the next year. This suggests a possible upside of 127.5% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:
  • Michael P. Bailey, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Erick J. Lucera, Chief Financial Officer
  • Michael N. Needle, Chief Medical Officer
  • Matthew Coulter, Vice President-Information Technology
  • Stefanie Solomon, Head-Compliance

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals CEO Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among AVEO Pharmaceuticals' employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.21%), Opaleye Management Inc. (1.88%), BlackRock Inc. (1.39%), Goldman Sachs Group Inc. (1.00%), Susquehanna International Group LLP (0.00%) and Geode Capital Management LLC (0.71%). Company insiders that own AVEO Pharmaceuticals stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends for AVEO Pharmaceuticals
.

Which institutional investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Opaleye Management Inc., Northern Trust Corp, Geode Capital Management LLC, Morgan Stanley, Morgan Stanley, and Citadel Advisors LLC.
View insider buying and selling activity for AVEO Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying AVEO Pharmaceuticals stock?

AVEO stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Ergoteles LLC, Renaissance Technologies LLC, Simplex Trading LLC, Vanguard Group Inc., Susquehanna Fundamental Investments LLC, Jump Financial LLC, and Tibra Equities Europe Ltd. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Michael Ferraresso, Michael P Bailey, and Peter W Sonsini.
View insider buying and selling activity for AVEO Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $6.74.

How much money does AVEO Pharmaceuticals make?

AVEO Pharmaceuticals has a market capitalization of $231.68 million and generates $6.02 million in revenue each year. The biopharmaceutical company earns $-35,580,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How many employees does AVEO Pharmaceuticals have?

AVEO Pharmaceuticals employs 94 workers across the globe.

When was AVEO Pharmaceuticals founded?

AVEO Pharmaceuticals was founded in 2001.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

Where are AVEO Pharmaceuticals' headquarters?

AVEO Pharmaceuticals is headquartered at 30 WINTER STREET, BOSTON MA, 02108.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at (617) 400-0101 or via email at [email protected].


This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.